Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis Feb 8, 2021
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter Dec 28, 2020
Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results Nov 12, 2020
Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis Nov 12, 2020
Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update Nov 5, 2020
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting Oct 9, 2020
